Cardiology · General Medicine
Infective Endocarditis
Also known as IE · Infective endocarditis · Subacute bacterial endocarditis · SBE
Infective endocarditis (IE) is a microbial infection of the endocardial surface, usually a heart valve, forming friable vegetations of platelets and fibrin that entrap organisms. It classically presents with fever, a new or changing murmur, and embolic, immunologic or septic phenomena. Diagnosis rests on blood cultures and echocardiography integrated through the Duke criteria. Management combines prolonged bactericidal antibiotics (benzylpenicillin/ceftriaxone ± gentamicin for streptococci; flucloxacillin for MSSA; vancomycin for MRSA) with early surgery for heart failure, uncontrolled infection or the prevention of embolism.
On this page & tools
Your progress
Saved locally on this device.
Exam tags
Red flags

Meet the patient
A 58-year-old man with a known bicuspid aortic valve is admitted with three weeks of low-grade fever, night sweats, and a "flu" that would not go. He has lost six kilograms. On his second morning on the ward he develops sudden weakness of his right arm that resolves over an hour, and the nurse notices tiny linear splinters under two of his fingernails.[11]
His blood pressure is normal, he is in sinus rhythm at 96, and a new soft diastolic murmur has appeared at the left sternal edge that was not documented at his last clinic visit. Three sets of blood cultures are drawn before any antibiotic is given.[1]
Two exam questions are now live and the same answer closes both: is this endocarditis, and is the vegetation going to kill him before the antibiotics work? Everything below exists to apply the Duke criteria without flinching, to draw three sets of cultures before antibiotics every time, and to know the three reasons to call the surgeon before the microbiology phone call.[3][4]
What endocarditis is — and why four weeks, IV, bactericidal
Infective endocarditis (IE) is a microbial infection of the endocardial surface of the heart — most often a heart-valve leaflet, but also the chordae tendineae, the mural endocardium, or the lining of a prosthetic valve or intracardiac device. The pathological hallmark is the vegetation, a mass of platelets and fibrin colonised by microorganisms, usually bacteria and rarely fungi. Once uniformly fatal, IE now kills roughly one in six patients during the index admission despite antibiotics and surgery, so early recognition and disciplined use of the Duke criteria matter.[3]
The central clinical skill in IE is integration, not a single test: the diagnosis combines clinical features, blood cultures and echocardiography through the structured Duke criteria, first proposed in 1994, modified in 2000 and updated again in 2023.[4][5][6] The therapeutic pivot is prolonged, high-dose, bactericidal, intravenous antibiotics — because the vegetation shelters organisms from phagocytes and bacteriostatic drugs — plus, in roughly half of patients, early surgery to deal with the mechanical and uncontrolled-infective complications that antibiotics alone cannot reverse.[1]
Classification — tempo, valve substrate, and portal
IE is classified along three axes that together predict the likely organism and the empiric regimen.[1][3]
By tempo
- Acute — days, aggressive, destroys a normal valve; S. aureus
- Subacute — weeks, indolent, on an abnormal valve; viridans streptococci
- Boundaries blurred as disease shifts to older, prosthetic, healthcare-exposed patients
By valve substrate
- Native-valve IE (NVE) — about 72 percent of cases
- Prosthetic-valve IE (PVE) — early (under 60 d) versus late (over 60 d) (ESC); under 1 yr versus over 1 yr in older texts
- Device-related (CIED) — pocket or lead infection seeding the tricuspid valve
By portal
- Community-acquired — viridans strep, classic dental or RHD
- Healthcare-associated (HAIE) — nosocomial or non-nosocomial (lines, haemodialysis)
- IV-drug-use (IVDU) — S. aureus, tricuspid or right heart
A few non-infectious mimics must be separated at the outset because they are culture-negative and demand entirely different management. Non-bacterial thrombotic endocarditis (NBTE, marantic) forms sterile vegetations in malignancy or a hypercoagulable state (Trousseau), and Libman-Sacks endocarditis forms sterile verrucous vegetations in systemic lupus erythematosus. Both produce systemic emboli and murmurs but negative blood cultures and no systemic sepsis — they are mimics of IE, not IE itself.[3]
Epidemiology — a disease that changed its face
The incidence of IE is 3 to 10 cases per 100,000 person-years in industrialised populations, with a clear upward drift over the last two decades driven by ageing, prosthetic material and healthcare exposure. In the United States the hospitalisation rate for IE roughly doubled between 1998 and 2009 in a nationwide analysis, with Staphylococcus aureus the dominant organism.[14] The incidence peaks in two groups: older adults with degenerative or prosthetic valves, and younger people who inject drugs.[1]
The modern face of the disease was drawn by the International Collaboration on Endocarditis–Prospective Cohort Study (ICE-PCS), which prospectively enrolled 2,781 adults with definite IE across 58 hospitals in 25 countries. It documented a median age of about 58 years, three-quarters native-valve IE, and S. aureus as the single commonest organism, with an in-hospital mortality near 18 percent and about half of patients needing surgery.[11]
Native-valve predisposition
- Rheumatic heart disease (still dominant where RHD persists)
- Bicuspid aortic valve, mitral valve prolapse, degenerative or calcific valve disease
- Congenital: VSD, PDA, coarctation, unrepaired cyanotic CHD
- Previous IE — the highest single-condition recurrence risk
Prosthetic and device
- Prosthetic valves — lifelong risk; about 1 to 6 percent at 5 yr
- CIED (pacemaker or ICD) leads — tricuspid seeding
- Intracardiac patches, occluder devices — highest in the first 6 months
Portal and host
- Intravenous drug use — repeated S. aureus bacteraemia; tricuspid
- Indwelling venous catheters, haemodialysis — coag-neg staph, S. aureus
- Poor dental hygiene — viridans streptococci
- Diabetes, immunosuppression, malignancy
The rise of prosthetic material, indwelling lines and S. aureus explains why the disease has shifted from young rheumatic-heart patients (where viridans streptococci dominated) to older, healthcare-exposed and prosthetic-valve patients, where S. aureus and coagulase-negative staphylococci now dominate.[1][11]
Pathophysiology — the six steps from sterile nidus to infected vegetation
Endocarditis begins where turbulent or high-velocity blood flow injures the endocardium. A jet from a stenotic, regurgitant or shunted lesion strikes the downstream endothelium and denudes it; platelets and fibrin deposit on the raw surface to form a sterile vegetation (non-bacterial thrombotic endocarditis, NBTE).[3] During a transient bacteraemia — from tooth-brushing, chewing, a healthcare procedure, an intravenous line or injection drug use — circulating organisms seed this nidus, adhere through surface adhesins (bacterial MSCRAMMs in staphylococci), multiply within the fibrin mesh sheltered from phagocytes, and an infected vegetation is established. Two cardinal rules follow:

- Vegetations form on the low-pressure, downstream surface where the jet lands. In aortic regurgitation they sit on the atrial face of the mitral valve (the AR jet strikes the anterior mitral leaflet — the "jet lesion"); in mitral regurgitation on the atrial surface of the mitral leaflets; in a VSD on the right (low-pressure) side of the defect and on the tricuspid leaflets opposite the jet; in aortic stenosis on the ventricular side of the aortic valve. Knowing where the jet lands predicts where to look on echocardiography.[3]
- The right heart is seeded first by bolus IV injection. A bolus of S. aureus injected into a vein passes through the right heart before the lungs filter it, so the tricuspid valve is the IV-drug-user's valve, and right-sided lesions shed septic pulmonary emboli to the lungs rather than systemic emboli to the brain and viscera.[3]
As the vegetation grows it may destroy valve tissue (leaflet perforation, chordal rupture, an abscess extending into the annulus or septum producing fistulae or atrioventricular conduction block) or fragment into the circulation, causing systemic embolisation. Left-sided lesions embolise to the brain (stroke), spleen, kidneys, mesentery and limbs; right-sided lesions seed the lungs as septic pulmonary emboli, infarcts and empyema.[3]
A parallel immune-complex response drives the immunologic phenomena — glomerulonephritis, Osler nodes, Roth spots and a positive rheumatoid factor — and a sustained inflammatory response produces the fever, anaemia and raised inflammatory markers that are the laboratory signature of the disease.[5]
The pathogenesis cascade — from sterile nidus to infected vegetation
This six-step cascade explains every preventive and therapeutic principle in IE: antibiotic prophylaxis targets the transient bacteraemia of step 3; bactericidal, prolonged, IV therapy overcomes the protected sanctuary of step 5; early surgery reverses the mechanical destruction and uncontrolled infection of step 6. It also explains the organisms' tropism: species with strong dextran-mediated adhesion (Streptococcus mutans, sanguinis) and fibronectin-binding staphylococci are over-represented because they adhere far more efficiently than transient contaminants such as E. coli or Pseudomonas, which rarely cause native-valve IE despite frequent bacteraemia.[3]
Causative organisms — by substrate and context
Knowing the likely organism from the clinical context drives empiric therapy. The table below is the working microbiology of IE every candidate must carry.[11][3]
Native-valve (community)
- Viridans streptococci (about 20 to 30 percent) — number 1 historically; dental source; *S. sanguinis, S. mutans, S. mitis, S. salivarius*
- S. aureus (about 30 percent) — now the commonest single organism; acute, destructive
- Enterococci (about 10 percent) — GU or GI source; *E. faecalis, E. faecium*
- HACEK (about 1 to 3 percent) — fastidious Gram-negatives
- S. gallolyticus (S. bovis) — screen the colon
Prosthetic valve
- Early (under 60 d or under 1 yr): coagulase-negative staph (*S. epidermidis*) — nosocomial acquisition during surgery; S. aureus; Gram-negatives
- Late (over 60 d or over 1 yr): resembles native-valve — streptococci, S. aureus, enterococci; also coag-neg staph
- Fungi (*Candida*) — early prosthetic, immunosuppressed
- Always add rifampicin (after bacteraemia clears) — biofilm penetration
IV-drug-use
- S. aureus over 60 percent (often MSSA, watch MRSA)
- Tricuspid valve (right-sided); septic pulmonary emboli
- Coag-neg staph, streptococci, Gram-negatives, Candida (especially heroin plus contaminated lemon juice)
- Polymicrobial or fungal raises the index for injection-drug use
Culture-negative
- Prior antibiotics — the commonest cause (organisms suppressed, not killed)
- Coxiella burnetii (Q fever) — anti-phase-I IgG over 1:800; treat with doxycycline plus hydroxychloroquine
- Bartonella spp. (henselae, quintana) — serology or PCR; homelessness, alcoholism, cat exposure
- Tropheryma whipplei, Brucella, Legionella, fungi — all need serology or PCR, not culture
The single most useful rule: the valve substrate and the clinical portal predict the organism, and the organism predicts the empiric regimen. A young dental-source native-valve case points to viridans streptococci and penicillin; a febrile prosthetic-valve patient three weeks after surgery points to coagulase-negative staph and vancomycin plus rifampicin; a febrile intravenous-drug user with pulmonary infiltrates points to S. aureus and the tricuspid valve.[11]
Clinical presentation — fever plus a murmur, then everything else
Presentation spans a fulminant septic illness to an indolent wasting disease, but the central thread is always fever plus a murmur plus evidence of embolic, immunologic or septic phenomena.[11]
History
The history is built from systemic, septic and embolic threads. Fever (often low-grade with chills, occasionally hectic) is present in about 90 percent of patients; an afebrile patient already on antibiotics does not exclude IE. Constitutional symptoms — malaise, anorexia, weight loss, night sweats, fatigue, myalgia and arthralgia — dominate the subacute presentation and may precede the murmur by weeks. Ask directly about new neurological symptoms (weakness, visual disturbance, headache — embolic stroke or mycotic aneurysm), chest or pleuritic pain and haemoptysis (septic pulmonary emboli in right-sided IE), abdominal or flank pain (splenic or renal infarct), and cold, painful extremities (limb embolus). A focused risk-factor history is essential: dental hygiene and recent procedures, intravenous drug use, indwelling lines, haemodialysis, prosthetic material, recent healthcare exposure, and known predisposing cardiac lesions.[11]
Examination — the peripheral stigmata
Examination looks for the new or changing murmur (the single most important bedside sign; a new regurgitant murmur suggests acute valve destruction) and the peripheral stigmata of embolisation and immune-complex deposition. Fever plus a murmur is the minimum diagnostic cluster, but a constellation of characteristic peripheral signs rewards the thorough examiner:[3]
- Petechiae (the commonest sign) — conjunctival, oral mucosa, palate, extremities.
- Splinter haemorrhages — linear subungual haemorrhages (non-specific; also trauma).
- Osler nodes — tender pea-sized nodules on finger and toe pulps.
- Janeway lesions — painless macules on palms and soles.
- Roth spots — boat-shaped haemorrhages with pale centres on fundoscopy.
- Clubbing — late, in subacute disease.
- Splenomegaly, arthralgia, heart failure, embolic stroke, acute limb ischaemia, renal infarct, mesenteric ischaemia.[5]
The two examinable "lesions on the extremities" are contrasted below — examiners love this distinction.[5]
Osler nodes
- Painful or tender
- Finger and toe pulp nodules
- Immunologic (immune-complex vasculitis)
- A minor Duke criterion
Janeway lesions
- Painless
- Macules on palms and soles
- Vascular (septic microemboli)
- A minor Duke criterion
Atypical presentation is the rule, not the exception, in vulnerable groups. The elderly may be afebrile or present with confusion, heart failure or stroke; the immunocompromised have blunted inflammatory signs; prosthetic-valve IE may present only as low-grade fever with a new regurgitant murmur or valve dehiscence; and right-sided (IVDU) IE may present with septic pulmonary emboli mimicking pneumonia rather than a classic systemic embolic illness.[1]
Tempo and clinical course
The tempo of IE splits the disease into two clinical archetypes, though modern practice blurs them. Recognising the tempo predicts the organism, the urgency and the prognosis.[11]
Acute versus subacute IE — the two archetypes
The differential — IE masquerading, and mimics of IE
The diagnostic challenge runs in two directions: IE masquerading as other febrile or embolic illnesses, and non-infectious vegetations mimicking IE. A structured differential with a discriminator for each is below.[1][3]
Marantic or NBTE
- Sterile vegetations in malignancy or hypercoagulability
- Cultures negative; no systemic sepsis
- Look for underlying adenocarcinoma or Trousseau
Libman-Sacks (SLE)
- Sterile verrucous vegetations on the mitral or aortic valve
- ANA or dsDNA positive, other SLE features
- Cultures negative; immune-mediated
Atrial myxoma
- A left atrial mass mimics mitral stenosis plus emboli
- Systemic febrile illness, positional murmur
- Echo resolves; cultures negative
FUO or sepsis mimic
- Lymphoma, TB, abscess, autoimmune
- Echo negative; no typical organisms
- Persistent fever without vegetation
Pulmonary embolism
- Right-sided IE mimics PE — pleuritic pain, infiltrates
- Cultures plus echo distinguish
- Septic emboli are cavitating and peripheral
Persistently negative cultures with a convincing syndrome raise culture-negative IE (prior antibiotics — the commonest cause — or fastidious or intracellular organisms: Coxiella burnetii, Bartonella spp., Tropheryma whipplei, Brucella) rather than excluding the diagnosis. These need serology and PCR rather than more culture bottles.[1][6]
Bedside assessment — three sets before antibiotics, every time
The single most important investigation is three sets of blood cultures drawn from separate venepuncture sites, spaced in time, before antibiotics wherever possible — because the aetiologic agent and its susceptibility, which dictate weeks of therapy, come from these cultures. In a patient with suspected subacute IE who is haemodynamically stable, it is worth waiting the few hours for three cultures drawn over a day before starting antibiotics. In sepsis or septic shock, however, do not delay empiric antibiotics to wait for cultures: draw them and treat immediately.[3]
Examine for the new or changing murmur (a new regurgitant murmur suggests acute valve destruction and impending heart failure) and the peripheral stigmata above. Examine the fundus for Roth spots, the abdomen for splenomegaly and tenderness (splenic infarct), the urine for microscopic haematuria, and perform a focused neurological examination for an embolic stroke.[1]
A new atrioventricular block — PR prolongation or higher — is a near-pathognomonic bedside clue to a perivalvular aortic-root abscess and mandates transoesophageal echocardiography and urgent surgical referral. A serial ECG showing progressive PR prolongation in a febrile patient with IE is, for practical purposes, an abscess until proven otherwise.[1]
Echocardiography — TTE first, TOE whenever suspicion persists
Echocardiography is the imaging cornerstone. A transthoracic echo (TTE) is first-line to detect vegetations and grade regurgitation and ventricular function, but its sensitivity for vegetations is only about 60 percent, and it is especially limited for prosthetic valves, small vegetations and posterior structures. Transoesophageal echo (TOE) — sensitivity above 90 percent for vegetations and abscess — is mandatory whenever TTE is negative but suspicion persists, for all prosthetic-valve IE, to detect perivalvular abscess or fistula, and to characterise vegetations before surgery.[3][1]
Transthoracic echo (TTE)
- First-line, non-invasive, bedside
- Sensitivity for vegetations about 60 percent (40 to 75 percent); lower for prosthetic, small or posterior lesions
- Specificity over 90 percent when a vegetation is seen
- Adequate in many native-valve cases with good windows
Transoesophageal echo (TOE)
- Sensitivity over 90 percent for vegetations and abscess
- Mandatory for all prosthetic valves, suspected abscess or fistula, and a negative TTE with high suspicion
- Required pre-operatively and to monitor therapy when indicated
- Detects perivalvular complications a TTE misses
The choice between TTE and TOE follows a simple rule: start with TTE in every suspected case, but if the clinical probability remains moderate-to-high (positive blood cultures, prosthetic valve, new murmur, staphylococcal bacteraemia, persistent fever) proceed to TOE regardless of the TTE result — a negative TTE never excludes IE, and a positive TTE may reveal an abscess or fistula that changes management from medical to surgical.[3]
Blood-culture technique deserves the same rigour as the imaging. Draw three sets (aerobic and anaerobic bottles per set) from three separate venepuncture sites, spaced at least 30 to 60 minutes apart (or, in urgent sepsis, drawn sequentially without undue delay), from different sites — never from existing lines unless a line-draw is specifically being compared. Use rigorous skin antisepsis (chlorhexidine-alcohol, allow to dry) to minimise contamination with coagulase-negative staphylococci, whose single positive bottle is a contaminant, not a diagnosis. The yield falls sharply after antibiotics begin — by 40 to 50 percent within hours — which is why cultures before antibiotics are paramount; if antibiotics have already been given, delay repeat cultures to allow suppressed organisms to recover.[3]
Investigations — the table that frames the work-up
| Test | Why it matters |
|---|---|
| Blood cultures (3 sets, separate sites, before antibiotics) | The keystone — identifies organism and susceptibility, drives weeks of therapy |
| Echocardiography — TTE then TOE | Visualises the vegetation, abscess, dehiscence, regurgitation; a major Duke criterion |
| FBC | Normocytic anaemia, neutrophil leucocytosis (acute), thrombocytopenia |
| CRP or ESR | Raised in over 90 percent; tracks response to therapy |
| U&E, LFTs | Baseline renal and hepatic function; AKI from sepsis, emboli or immune-complex GN |
| ECG | Baseline; new PR prolongation or AV block means an aortic-root abscess |
| Urinalysis | Microscopic haematuria (and red-cell casts if glomerulonephritis) — a minor criterion |
| Serology or PCR | For culture-negative IE: Coxiella (anti-phase-I IgG over 1:800), Bartonella, Brucella, Tropheryma |
| [18F]FDG PET or CT | A major criterion in the 2023 Duke-ISCVID for abnormal uptake around prosthetic valves or grafts (ESC) |
Bloods usually show a normocytic, normochromic anaemia of chronic disease, a leucocytosis (marked in S. aureus, modest or absent in subacute disease), raised CRP and ESR, and often deranged renal function. Urinalysis showing microscopic haematuria supports an immunologic process (glomerulonephritis). The rheumatoid factor may be positive (an immunologic minor criterion).[5]
The Duke criteria — the framework examiners quote
Because no single finding confirms IE, the diagnosis integrates blood-culture and echocardiographic findings (major criteria) with predisposition, fever, vascular phenomena, immunologic phenomena and supporting microbiology (minor criteria) into the categories of definite, possible and rejected endocarditis. The criteria were proposed by the Duke Endocarditis Service in 1994 (two major, six minor; definite or possible or rejected),[4] modified in 2000 (redefining "possible" as one major plus one minor or three minor; promoting S. aureus bacteraemia to a major criterion),[5] and updated again in 2023 by Duke-ISCVID, adding [18F]FDG PET or CT and SPECT or CT abnormal uptake, cardiac CT detecting perivalvular complications, intraoperative evidence, and 16S or 18S rRNA PCR of excised tissue as microbiologic or imaging criteria.[6]

MAJOR criteria (two):[4]
- A typical positive blood culture for IE:
- (i) two separate blood cultures positive for typical microorganisms — viridans streptococci, S. aureus, the HACEK group, or community-acquired enterococci — in the absence of a primary focus; OR
- (ii) persistently positive blood cultures — at least two positive cultures drawn more than 12 hours apart, or a majority of three or more separate cultures with the first and last drawn at least one hour apart; OR
- (iii) a single positive blood culture for Coxiella burnetii or an anti-phase-I IgG antibody titre greater than 1:800.
- Endocardial involvement on echo:
- an oscillating intracardiac mass (vegetation) on a valve or supporting structures, in the path of regurgitant jets, or on implanted material; OR
- an abscess; OR
- new partial dehiscence of a prosthetic valve; OR
- new valvular regurgitation (a worsening or changing of a pre-existing murmur is insufficient).[4][5]
MINOR criteria (five):[5]
- Predisposition — a predisposing heart condition or intravenous drug use.
- Fever — temperature 38 degrees C or higher.
- Vascular phenomena — arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial haemorrhage, conjunctival haemorrhages, Janeway lesions.
- Immunologic phenomena — glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor.
- Microbiological evidence — a positive blood culture not meeting a major criterion, or serologic evidence of active infection with an organism consistent with IE.[4][5]

The number rule for definite IE is 2-1-3 / 5: two major, OR one major plus three minor, OR five minor — or pathologic evidence of IE on excised tissue or a positive culture of an embolic specimen. Possible IE meets one major plus one minor, or three minor. IE is rejected if there is a firm alternative diagnosis, resolution with less than four days of antibiotics, or no pathologic evidence at surgery or autopsy.[4][5]
Resuscitation — sepsis and heart failure in the first hours
Resuscitation addresses the sepsis and the heart failure that dominate the first hours, while securing the microbiological diagnosis.[1][3]
- Septic or septic-shock IE: give oxygen and insert two large-bore IV cannulae, draw three sets of blood cultures from separate sites before antibiotics, then start empiric IV antibiotics immediately — do not delay therapy in sepsis. Give crystalloid fluids cautiously and use vasopressors (noradrenaline first-line) for shock; correct electrolytes; monitor urine output, lactate and renal function. Follow the sepsis-six bundle and escalate to critical care early.
- Acute severe regurgitation and pulmonary oedema: this is the commonest surgical emergency in IE. Sit the patient up, give high-flow oxygen, IV furosemide, a vasodilator (glyceryl trinitrate infusion if blood pressure permits) and non-invasive ventilation for respiratory failure — but these measures only buy time. Definitive treatment is urgent valve surgery, and surgical referral must be made at the moment the diagnosis of acute severe regurgitation is made, without waiting for culture completion.[1]
- Embolic stroke: maintain perfusion and oxygenation, avoid hypotension, and involve neurology and cardiothoracic surgery; the question of early surgery after stroke is complex and time-dependent.[1]
The non-negotiable rule: three sets of blood cultures before antibiotics, every time — the whole of definitive therapy hangs on what these cultures grow.[3]
Definitive therapy — antibiotics, surgery, prevention
Definitive therapy rests on three pillars: bactericidal antibiotic therapy directed at the organism and its MIC, early surgery for mechanical or uncontrolled complications, and prevention of recurrence through prophylaxis.[3][10]
Empiric antibiotic therapy (before culture results)
Empiric therapy is dictated by the valve substrate and the clinical context. Every regimen below combines a cell-wall-active bactericidal agent (a beta-lactam or glycopeptide) with cover for the most likely organisms; doses assume normal renal function and must be adjusted to MIC and renal function once cultures return.[1][3]
| Scenario | Empiric regimen (drug plus dose plus route) |
|---|---|
| Native-valve, community-acquired | Ampicillin-sulbactam 3 g IV 6-hourly (or benzylpenicillin 1.2 g IV 4-hourly) plus gentamicin 1 mg/kg IV 8-hourly; add flucloxacillin 2 g IV 6-hourly if S. aureus is suspected (cellulitis, IVDU). ESC: ampicillin plus gentamicin plus flucloxacillin |
| Native-valve, broad or unknown (severe sepsis, healthcare exposure) | Vancomycin 15 mg/kg IV 12-hourly (target trough 15 to 20) plus gentamicin 1 mg/kg IV 8-hourly plus cefepime 2 g IV 8-hourly |
| Prosthetic valve (early, under 1 yr, or any PVE pending cultures) | Vancomycin 15 mg/kg IV 12-hourly plus gentamicin 1 mg/kg IV 8-hourly plus cefepime 2 g IV 8-hourly plus rifampicin 300 to 450 mg IV or PO 12-hourly (add rifampicin only once bacteraemia has cleared, typically after 3 to 5 days, to avoid resistance) |
| IV-drug-use (tricuspid or right-sided) | Flucloxacillin 2 g IV 6-hourly (MSSA likely); vancomycin 15 mg/kg IV 12-hourly if there is MRSA risk (nosocomial, known colonisation). Gentamicin is generally not needed in uncomplicated right-sided MSSA IE |
| Culture-negative or fastidious suspected | Vancomycin plus gentamicin plus cefepime (with serology for Coxiella, Bartonella); consider doxycycline plus hydroxychloroquine if Coxiella is confirmed |
Definitive (organism-directed) therapy
Once the organism and MIC are known, therapy is narrowed and prolonged. Total duration is counted from the first day of effective antibiotics (the first negative culture day for some guidelines).[3][9]
- Penicillin-susceptible viridans streptococci (MIC at or below 0.12 mg/L): benzylpenicillin (penicillin G) 1.2 g (2 MU) IV 4-hourly (total 12 to 18 MU per day) — or ceftriaxone 2 g IV once daily for 4 weeks. A 2-week course adding gentamicin 1 mg/kg IV 8-hourly for the first 2 weeks is acceptable in selected uncomplicated cases (young, native valve, MIC at or below 0.12, no emboli, prompt response).[3]
- Penicillin-relatively-resistant streptococci (MIC over 0.12 to at or below 0.5 mg/L): benzylpenicillin or ceftriaxone for 4 weeks plus gentamicin 1 mg/kg IV 8-hourly for the first 2 weeks.[3]
- MSSA native-valve IE: flucloxacillin (or nafcillin or oxacillin) 2 g IV 4- to 6-hourly for 6 weeks; gentamicin 1 mg/kg IV 8-hourly for the first 3 to 5 days is optional and no longer routine. For uncomplicated right-sided MSSA IE in IVDU, a 2-week course of flucloxacillin plus gentamicin may suffice.[3]
- MRSA IE: vancomycin 15 mg/kg IV 12-hourly (or 25 to 30 mg/kg per day continuous or intermittent, trough 15 to 20) for 6 weeks; daptomycin 6 to 10 mg/kg IV daily is an alternative. Gentamicin is not routinely added (nephrotoxicity, no benefit).[9]
- Enterococcal IE (ampicillin-sensitive): ampicillin 2 g IV 4-hourly plus gentamicin 1 mg/kg IV 8-hourly for 4 to 6 weeks; for aminoglycoside-resistant or HLAR strains use ampicillin plus ceftriaxone (a synergistic double-beta-lactam) for 6 weeks. Vancomycin replaces ampicillin for ampicillin-resistant strains.[3]
- HACEK IE: ceftriaxone 2 g IV daily for 4 weeks (ampicillin-sulbactam is an alternative).[13]
- Culture-negative IE: treat the underlying organism once identified — doxycycline plus hydroxychloroquine for Coxiella (at least 18 months), gentamicin (or ceftriaxone) plus doxycycline for Bartonella, trimethoprim-sulfamethoxazole for Tropheryma whipplei.[6]
Surgery — the three ESC indications
Early surgery (during the initial antibiotic course) is needed in roughly half of patients, driven by three ESC-defined indications.[1][2]
Heart failure
- The commonest indication (about 60 to 70 percent of operated cases)
- Acute severe regurgitation from valve destruction or rupture
- Urgent surgery regardless of organism or culture status
Uncontrolled infection
- Persistent bacteraemia or fever over 5 to 7 days on correct antibiotics
- Perivalvular extension — abscess, fistula, heart block
- Fungal or multi-resistant organisms not responding medically
Prevention of embolism
- Large (over 10 mm), mobile vegetations with embolic risk
- Prior embolic event with a persisting large vegetation
- Highest embolic risk in the first days of therapy
Surgery is also indicated for prosthetic-valve IE with dehiscence or obstruction, large vegetations from organisms difficult to eradicate (fungi), and CIED infection (requiring complete device and lead extraction). The operation is usually valve replacement with a mechanical or bioprosthetic prosthesis, but valve repair is increasingly used for isolated mitral or tricuspid lesions where feasible, avoiding long-term anticoagulation.[1]
The clearest evidence for surgery as embolic prevention is Kang and colleagues' randomised trial of early surgery (within 48 hours) versus conventional treatment in left-sided IE with large vegetations: early surgery reduced the composite of in-hospital death and embolic events (3 percent versus 23 percent, hazard ratio 0.10) — a benefit driven entirely by fewer embolic events, since all-cause mortality alone was not significantly different (3 percent versus 5 percent).[7]
The decision to operate, and how urgently, follows a structured assessment of the indication and the operative risk.[1]
Deciding on and timing surgery in IE
Is there heart failure from acute severe regurgitation?
If yes — URGENT surgery, regardless of organism, cultures or duration of antibiotics. The commonest and most lethal indication; do not delay for medical stabilisation.
Is there uncontrolled infection?
Persistent bacteraemia or fever beyond 5 to 7 days of correct antibiotics, a perivalvular abscess or fistula, new AV block, or a fungal or multiresistant organism — surgery (urgent or early) is usually needed.
Is there a high embolic risk?
A large (over 10 mm) mobile vegetation, a prior embolus with residual vegetation, or a rapidly growing vegetation in the first week — early surgery within days, while the embolic-risk window is open.
What is the operative risk?
Age, comorbidity, prosthetic versus native, neurological status. A recent stroke requires balancing haemorrhagic-transformation risk against the cardiac indication; delay 1 to 2 weeks post-ischaemic stroke if feasible.
Replace versus repair
Valve replacement (mechanical or bioprosthesis) is standard; mitral or tricuspid repair is increasingly used for localised destructive lesions where feasible, sparing lifelong anticoagulation.
Prophylaxis — the great international divergence
Special situations you will actually meet
Native-valve (community)
- Viridans streptococci, S. aureus, enterococci, HACEK
- Empiric: benzylpenicillin or ampicillin plus gentamicin, with or without flucloxacillin
- Often subacute unless it is S. aureus
Prosthetic valve
- Early (under 60 d or under 1 yr): coag-neg staph (S. epidermidis), S. aureus, Gram-negatives
- Late (over 60 d or over 1 yr): resembles native-valve (strep, staph, enterococcus)
- Empiric: vancomycin plus gentamicin plus cefepime plus rifampicin (after bacteraemia clears)
IV drug use
- S. aureus (over 60 percent); often MSSA, watch MRSA
- Tricuspid valve (right-sided); septic pulmonary emboli
- Empiric: flucloxacillin (MSSA) or vancomycin (MRSA); often curable medically
Healthcare-associated
- S. aureus (including MRSA), coag-neg staph, enterococcus, Candida
- Lines, haemodialysis, recent procedures
- Empiric: vancomycin-based plus Gram-negative cover
Culture-negative IE follows prior antibiotics (the commonest reason — organisms suppressed, not killed) or fastidious or intracellular organisms (Coxiella, Bartonella, Tropheryma, Brucella, Legionella) and fungi (Candida, Aspergillus), which need serology or PCR rather than more culture bottles. The 2023 Duke-ISCVID update explicitly adds 16S or 18S rRNA PCR and metagenomic sequencing of excised tissue as microbiologic criteria, reflecting this reality.[6]
Streptococcus gallolyticus (formerly S. bovis) bacteraemia or IE mandates colonoscopy, because of its strong (about 30 percent) association with advanced colonic neoplasia — finding the organism in a blood culture is itself an indication to screen the colon.[1] Fungal IE (Candida, Aspergillus) occurs with immunosuppression, long-term indwelling lines, total parenteral nutrition and IV drug use, produces large friable vegetations with major embolic risk, and has a poor prognosis — it almost always needs surgery combined with prolonged antifungal therapy (liposomal amphotericin B or an echinocandin, step-down to fluconazole).[1]
Cardiac-implantable electronic device (CIED) infections of the pocket or lead may seed the tricuspid valve; they usually require complete percutaneous or surgical device and lead extraction in addition to targeted antibiotics, as infection of the insulated lead is essentially impossible to sterilise medically.[1]
HACEK
Haemophilus species (H. aphrophilus, H. parainfluenzae)
Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans
Cardiobacterium hominis
Eikenella corrodens
Kingella kingae
The HACEK group are slow-growing, fastidious Gram-negative oropharyngeal commensals that need prolonged incubation (now mostly recovered in modern automated blood-culture systems within 5 days). They cause about 1 to 3 percent of IE, typically subacute on native valves, and are uniformly susceptible to ceftriaxone 2 g IV daily for 4 weeks.[13]
How patients with endocarditis come to harm (the preventable list)
- Treating S. aureus bacteraemia as a simple line infection without echocardiographic exclusion of IE — significant SAB carries a high probability of endocarditis; suboptimal evaluation (omitting echo, too-short antibiotics) is associated with worse outcome.[12]
- Delaying surgery for heart failure in the hope of medical stabilisation — heart failure is the commonest indication for surgery and the commonest cause of death; the threshold to operate is appropriately low.[1]
- Missing a perivalvular abscess — a new AV block or persistent fever on correct antibiotics is an abscess until proven otherwise; only TOE and surgery will resolve it.[1]
- Over-diagnosing IE from a single positive culture — one bottle growing a coagulase-negative staphylococcus is a skin contaminant, not PVE; the Duke criteria require persistence.[5]
- Drawing cultures after antibiotics — the yield falls by 40 to 50 percent within hours; three sets before antibiotics, every time.[3]
- Forgetting rifampicin's timing in PVE — add it only after bacteraemia clears (3 to 5 days), or you breed resistance.[1]
- Missing the S. bovis colonoscopy — finding gallolyticus in a blood culture is itself an indication to screen the colon for neoplasia.[1]
Prognosis and disposition
Despite modern antibiotics and surgery, IE remains lethal, with in-hospital mortality of about 15 to 20 percent for native-valve IE, 20 to 40 percent for prosthetic-valve IE, and 40 to 60 percent when S. aureus is the organism. One-year mortality approaches 30 percent.[11][3] Adverse prognostic features are the same factors that predict death and drive surgery: S. aureus infection, prosthetic-valve involvement, heart failure, older age, perivalvular complications (abscess, conduction block), embolic events, large vegetations, and healthcare-associated acquisition.[11]
Conversely, viridans-streptococcal infection is comparatively favourable, and indicated surgery is itself protective — a reminder that the threshold to operate in IE is appropriately low, and that delaying surgery for heart failure in the hope of medical stabilisation is a recurring and lethal error.[11]
Disposition requires 4 to 6 weeks of intravenous therapy (often via a peripherally inserted central catheter, with outpatient parenteral antibiotic therapy once the patient is stable, afebrile, culture-negative and surgically cleared), serial inflammatory markers and repeat echocardiography to document shrinking vegetations and stable valve function, dental clearance (eliminate the oral source of bacteraemia), infectious-diseases, cardiology and (where relevant) cardiothoracic-surgery follow-up, and patient education on the recurring risk and the need for prophylaxis. In S. aureus bacteraemia, adherence to infectious-diseases specialist recommendations (including echocardiographic evaluation) measurably improves outcome.[12]
Pregnancy and special populations
| Group | Considerations |
|---|---|
| Pregnancy | Rare but dangerous; right-sided IVDU IE is more common. Penicillins, cephalosporins are safe; vancomycin is acceptable; avoid aminoglycosides (fetal ototoxicity) and tetracyclines. Cardiopulmonary bypass in pregnancy is feasible if heart failure mandates urgent surgery |
| Prosthetic valve | Lifelong risk; early (under 60 d) coag-neg staph and nosocomial organisms, late resembles native-valve. Add rifampicin after bacteraemia clears; TOE mandatory; surgery for dehiscence or obstruction |
| Elderly | Often afebrile; present with confusion, heart failure or stroke; more comorbidity and prosthetic or degenerative valves; higher mortality; a lower threshold to image |
| Immunocompromised or lines | Consider fungal (Candida, Aspergillus) and resistant organisms; remove indwelling lines; broaden empiric cover |
| IV drug use | Right-sided (tricuspid) IE, younger, often curable medically in 2 to 6 weeks; high recurrence if injection continues; address addiction |
| Paediatric or CHD | Often on congenital substrate (VSD, tetralogy, post-surgical repair); surgery and anticoagulation considerations differ |
Evidence, guidelines and regional differences
The evidence base for IE rests on a small number of landmark studies and a set of converging guidelines that now agree on most points but diverge sharply on prophylaxis.[1][3]
- ESC 2023 (Delgado) versus AHA or IDSA 2015 (Baddour): both endorse the Duke framework and the three surgical indications (heart failure, uncontrolled infection, prevention of embolism). The ESC 2023 guideline is the most current and adds [18F]FDG PET or CT and cardiac CT as major diagnostic criteria, mirroring the 2023 Duke-ISCVID update; the AHA statement is older but its antibiotic recommendations remain standard.[1][3][6]
- Kang 2012 RCT is routinely (and wrongly) summarised as "early surgery saves lives" — it did not show a significant mortality reduction. Its benefit was a drop in embolic events within a composite endpoint (death plus emboli), which is exactly how it should be cited. Subsequent observational data and the 2023 ESC guidance accept early surgery for large (over 10 mm) mobile vegetations with high embolic risk, especially after a first embolic event.[7]
- Prophylaxis — the great divergence: the AHA (US) restricts prophylaxis to high-risk cardiac lesions for dental procedures only; NICE (UK) went further and recommends no routine antibiotic prophylaxis at all, emphasising oral hygiene instead; ESC (Europe) takes a middle position, recommending prophylaxis for the highest-risk group for dental procedures. India (ICMR or NCDC) does not mandate routine dental prophylaxis but recognises the high-risk groups; empiric antibiotic choices in India must account for local resistance (high community MRSA, ESBL Gram-negatives).[8]
- IDSA MRSA guidance (Liu 2011) remains the reference for vancomycin dosing (trough 15 to 20 mg/L), duration (6 weeks for native, at least 6 weeks for prosthetic), and the option of daptomycin for vancomycin failures or intolerance.[9]
- Controversy: routine surgery for large vegetations over 10 mm without embolism remains debated; observational data suggest benefit is concentrated in the first week after presentation, before the embolic risk falls.[7]
The mantra, and the viva honesty line
Infective endocarditis — the memory hooks
FEVER
the minimum diagnostic cluster — then hunt for embolic, immunologic and septic phenomena
the two major Duke criteria — three culture sets before antibiotics, TTE then TOE
forms on the low-pressure surface where the jet lands — atrial in MR, ventricular in AS, right side of a VSD
for heart failure (the commonest), uncontrolled infection, or a large mobile vegetation with embolic risk
in prosthetic-valve IE, add rifampicin only once bacteraemia clears (3 to 5 days) to avoid resistance
The mantra: three sets before antibiotics, Duke to diagnose, four weeks of a bactericidal IV drug — and call the surgeon for failure, fever, or a flying vegetation.[1][3]
Ward-round test — three stems, thirty seconds each
Stem 1 — the bicuspid-valve patient from the top of the topic (answer)
A 58-year-old with a bicuspid aortic valve, three weeks of fever, night sweats and weight loss, a transient ischaemic attack, splinter haemorrhages, and a new diastolic murmur at the left sternal edge. Three cultures grow viridans streptococci. What is the Duke category and the definitive therapy? Model: Definite IE — two major criteria alone suffice (typical positive blood culture plus new valvular regurgitation on echo, once confirmed); the predisposition, fever and vascular phenomena are supporting minors. Definitive therapy for penicillin-susceptible viridans streptococci is benzylpenicillin 1.2 g (2 MU) IV 4-hourly or ceftriaxone 2 g IV once daily for 4 weeks (a 2-week course with gentamicin is acceptable only if uncomplicated). The transient ischaemic attack is an embolic event — image for a vegetation; if it is large and mobile, early surgery reduces further emboli (Kang).[3][7]
Stem 2 — the IV-drug user with cavitating lungs (answer)
A 29-year-old man who injects heroin presents with fever, pleuritic chest pain and cavitating peripheral lung infiltrates; blood cultures grow Staphylococcus aureus. Which valve, which mechanism, and which drug? Model: Right-sided (tricuspid) IE in an IVDU — the bolus of S. aureus passes through the right heart first and seeds the tricuspid valve, shedding septic pulmonary emboli to the lungs (hence the cavitating peripheral infiltrates). For MSSA, definitive therapy is flucloxacillin 2 g IV 6-hourly (vancomycin 15 mg/kg 12-hourly if MRSA); uncomplicated right-sided MSSA IE may be curable in 2 weeks. Address the addiction — recurrence is high if injection continues.[3]
Stem 3 — the prosthetic-valve patient with a widening PR (answer)
A 66-year-old with a mechanical aortic valve, six weeks post-surgery, has persistent fever despite five days of vancomycin plus gentamicin. Her ECG now shows first-degree AV block that was not there on admission. What has happened, and what is the next move? Model: Perivalvular extension — an aortic-root abscess — until proven otherwise. New AV block in prosthetic-valve IE is a near-pathognomonic bedside clue and a surgical emergency. Order a transoesophageal echo to confirm the abscess or fistula, add rifampicin (now that bacteraemia is being controlled) for biofilm penetration, and call the surgeon — an abscess will not resolve medically. Empiric cover must include coagulase-negative staph (vancomycin) given the early prosthetic timing.[1][3]
References
- [1]Delgado V, Ajmone Marsan N, et al. 2023 ESC Guidelines for the management of endocarditis Eur Heart J, 2023.PMID 37622656
- [2]Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J, 2015.PMID 26320109
- [3]Baddour LM, Wilson WR, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association Circulation, 2015.PMID 26373316
- [4]Durack DT, Lukes AS, et al. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service Am J Med, 1994.PMID 8154507
- [5]Li JS, Sexton DJ, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis Clin Infect Dis, 2000.PMID 10770721
- [6]Fowler VG, Durack DT, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria Clin Infect Dis, 2023.PMID 37138445
- [7]Kang DH, Kim YJ, et al. Early surgery versus conventional treatment for infective endocarditis N Engl J Med, 2012.PMID 22738096
- [8]Wilson W, Taubert KA, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group Circulation, 2007.PMID 17446442
- [9]Liu C, Bayer A, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis, 2011.PMID 21208910
- [10]Baddour LM, Wilson WR, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America Circulation, 2005.PMID 15956145
- [11]Murdoch DR, Corey GR, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study Arch Intern Med, 2009.PMID 19273776
- [12]Fowler VG Jr, Sanders LL, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients Clin Infect Dis, 1998.PMID 9770144
- [13]Sharara SL, Tayyar R, et al. HACEK endocarditis: a review Expert Rev Anti Infect Ther, 2016.PMID 27124204
- [14]Bor DH, Woolhandler S, Nardin R, Brusch J Infective endocarditis in the U.S., 1998-2009: a nationwide study PLoS One, 2013.PMID 23527296